Core Concepts
Preoperative MRI can identify rectal cancer patients who can avoid neoadjuvant chemoradiation therapy.
Abstract
The content discusses the use of preoperative MRI to assess the mesorectal fascia (MRF) in rectal cancer patients to determine the need for neoadjuvant chemoradiation therapy. Key points include:
Guidelines recommend CRT before surgery for stage II-III rectal cancer.
Concerns about overtreatment have led to the search for less intensive treatment approaches.
A German study used preoperative MRI to assess MRF involvement in 884 patients with rectal cancer.
Patients with clear MRFs proceeded directly to total mesorectal excision, resulting in low locoregional recurrence rates.
Neoadjuvant CRT did not offer significant advantages over optimized surgery for patients with clear MRFs.
The study suggests restricting neoadjuvant chemoradiation therapy to high-risk patients.
Concerns about reproducibility and the need for expertise in discerning MRF involvement were raised.
Results showed lower distant metastases and rectal cancer-related deaths in the upfront surgery group.
The study was funded by Johannes Gutenberg University Mainz, with no relevant financial relationships reported by the investigators.
Stats
The 5-year locoregional recurrence rate was just 2.9% in patients with clear MRFs.
Almost 6% of patients who received neoadjuvant CRT had a locoregional recurrence within 5 years of TME.
The 5-year rate of distant metastases was 15.9% in the upfront surgery group vs 30.5% in the nCRT arm.
11% of the upfront surgery group died of rectal cancer during follow-up vs 21.8% of the nCRT arm.
Quotes
"This is another paper that pretty much confirms the assumption that we overtreat many patients with rectal cancer." - Alan Venook, MD